Vinogradova T.N. Vinogradova

Vinogradova T.N. Vinogradova

Auto-generated profile, based on publicly available information

Vinogradova T.N. Vinogradova

Center for the prevention and control of AIDS and infectious diseases

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2022 in Viruses
Verified
Journal Article
Open access
PDF file
MSMarina Siljic
Marina Siljic
VCValentina Cirkovic
Valentina Cirkovic
Luka Dragoljub JovanovicLuka Dragoljub Jovanovic
Luka Dragoljub Jovanovic
AAAnastasiia Antonova
Anastasiia Antonova
ALAleksey Lebedev
Aleksey Lebedev
MSMaja Stanojevic
Maja Stanojevic
The HIV/AIDS epidemic in Russia is among the fastest growing in the world. HIV epidemic burden is non-uniform in different Russian regions and diverse key populations. An explosive epidemic has been documented among people who inject drugs (PWID) starting from the mid-1990s, whereas presently, the majority of new infections are linked to sexual transmission. Nationwide, HIV sub-subtype A6 (previously called AFSU) predominates, with the increasing presence of other subtypes, namely subtype B and CRF063_02A. This study explores HIV subtype B sequences from St. Petersburg, collected from 2006 to 2020, in order to phylogenetically investigate and characterize transmission clusters, focusing on their evolutionary dynamics and potential for further growth, along with a socio-demographic analysis of the available metadata. In total, 54% (107/198) of analyzed subtype B sequences were found grouped in 17 clusters, with four transmission clusters with the number of sequences above 10. Using Bayesian MCMC inference, tMRCA of HIV-1 subtype B was estimated to be around 1986 (95% HPD 1984–1991), whereas the estimated temporal origin for the four large clusters was found to be more recent, between 2001 and 2005. The results of our study imply a complex pattern of the epidemic spread of HIV subtype B in St. Petersburg, Russia, still in the exponential growth phase, and in connection to the men who have sex with men (MSM) transmission, providing a useful insight needed for the design of public health priorities and interventions.

24 September 2024 in Journal Infectology
Verified
Journal Article
Open access
PDF file
AEA. I. Ermakov
A. I. Ermakov
NKN. N. Kotova
N. N. Kotova
TVT. N. Vinogradova
T. N. Vinogradova
DKDmitry Kireev
Dmitry Kireev
Early assessment of HIV incidence is an important public health tool for understanding the state of the epidemic in a particular area, identifying high-risk groups, and assessing the effectiveness of HIV prevention interventions.Objective. To assess the possibility of using the positivity rate (S/CO) in the HIV Ag/Ab immunoassay on the Alinity i analytical platform to determine the duration of infection during HIV screening.Materials and methods. The study included 316 HIV-infected patients with different infection durations. Immunochemical analysis was performed on an Alinity i automatic analyzer (Abbott Laboratories, USA) using the Alinity i HIV Ag/Ab Reagent Kit (Abbott Laboratories, Germany) in accordance with the manufacturer’s instructions.Results. Statistical analysis of 316 blood samples from HIV-infected patients at different stages of infection demonstrated the reactivity of the Alinity i HIV Ag/Ab test result and a dynamic increase in the positivity ratio during the first six months after the onset of the disease. Based on the data obtained, a threshold value (≤294 conventional units) was obtained for the positivity ratio, which allowed for a clear distinction between HIV-positive patients with a recent (<6 months) period of infection. At the same time, the sensitivity and specificity indicators for detecting recent infection in the CMIA analysis were 79,0% and 63,2%, respectively.Conclusion. The additional usage of the positivity ratio in the Alinity i HIV Ag/Ab CMIA analysis meets the acceptability criteria for assessing the duration of HIV infection and can be a useful tool for analyzing the stage of the epidemic in a particular territory.

20 September 2024 in Èpidemiologiâ i Infekcionnye Bolezni. Aktual’nye Voprosy
Verified
Journal Article
Closed access
PPPiskarev I.G. Piskarev
Piskarev I.G. Piskarev
OOOdinokova V.A. Odinokova
Odinokova V.A. Odinokova
MMMaslova I.A. Maslova
Maslova I.A. Maslova
PVPetrova V.G. Petrova V
Petrova V.G. Petrova V
VVVinogradova T.N. Vinogradova
Vinogradova T.N. Vinogradova
S«St. Petersburg Fund For Preventive Programs Of Socially Significant Diseases «Astarta»
St. Petersburg Fund For Preventive Programs Of Socially Significant Diseases «Astarta»

25 September 2026 in Èpidemiologiâ i Infekcionnye Bolezni. Aktual’nye Voprosy
Verified
Journal Article
Closed access
CCChirskaya M.A. Chirskaya
Chirskaya M.A. Chirskaya
KKKhalezova N.B. Khalezova
Khalezova N.B. Khalezova
NMNikita Monakhov
Nikita Monakhov
SSSereda E.ZH. Sereda
Sereda E.ZH. Sereda
MMMyagkova O.S. Myagkova
Myagkova O.S. Myagkova
SDSaint Petersburg Saint Petersburg Center For The Prevention And Control Of Aids And Infectious Diseases
Saint Petersburg Saint Petersburg Center For The Prevention And Control Of Aids And Infectious Diseases

24 June 2025 in Journal Infectology
Verified
Journal Article
Open access
PDF file
EYE. B. Yastrebova
E. B. Yastrebova
ATA. G. Trishina
A. G. Trishina
SRS. Yu. Romanova
S. Yu. Romanova
TVT. N. Vinogradova
T. N. Vinogradova
The hepatitis B virus (HBV) and the disease it causes have been actively studied for over 50 years. Recent estimates provided by the World Health Organization indicate that approximately 1 in 22 (4.5%) individuals with chronic hepatitis B have antibodies to the hepatitis D virus (HDV). The exact global prevalence of hepatitis D remains unclear due to differences in the sensitivity and specificity of diagnostic tests and the lack of standardized testing systems. In Russia, patients with hepatitis D are not subject to mandatory registration, and the routes of transmission are similar to those of hepatitis B. The disease is often diagnosed at a late stage (e.g., liver cirrhosis) due to the lack of widespread targeted screening for HDV antibodies among HBsAg-positive patients; about two-thirds of patients are unaware of their infection status. The study of socio-epidemiological and clinical-laboratory characteristics of HIV-positive patients co-infected with chronic hepatitis B and delta agent is of significant scientific and practical interest.The aim of this study was to conduct a comparative analysis of socio-epidemiological and clinical-laboratory features of HIV-positive patients with chronic hepatitis B and delta agent compared to patients without HIV infection. Materials and Methods. The study included 50 patients under observation at the city AIDS center, of whom 24 were diagnosed with HIV infection and chronic hepatitis B+D (Group 1), and 26 had chronic hepatitis B+D without HIV infection (Group 2). The mean age of the patients was 46.7±0.5 years, with 34 males (68.0%) and 16 females (32.0%).Results and Discussion. The “social profile” of HIV-positive patients with chronic hepatitis B+D is characterized as follows: these individuals are typically intravenous drug users, lack higher education, are unemployed, not in formal marriages, and have an HIV infection duration of more than 8 years, often with stage 4A HIV infection according to the Russian classification. All patients in this group were receiving antiretroviral therapy, and the vast majority were also on antiviral therapy for chronic hepatitis. Conclusion. Thus, HIV-positive patients with chronic hepatitis B+D significantly differ from those with chronic hepatitis B+D alone in terms of infection routes, education level, marital status, disease duration, aminotransferase levels, and hematological abnormalities. In both groups, severe liver fibrosis (F3-F4) predominated, accounting for a total of 70%. Antiviral therapy for chronic hepatitis B+D using bulevirtide represents a promising direction for the elimination of HBV and HDV and requires further study and analysis.

3 November 2023 in Èpidemiologiâ i Infekcionnye Bolezni. Aktual’nye Voprosy
Verified
Journal Article
Closed access
PPPiskarev I.G. Piskarev
Piskarev I.G. Piskarev
YYYeritsyan K.YU. Yeritsyan
Yeritsyan K.YU. Yeritsyan
SSShagina A.B. Shagina
Shagina A.B. Shagina
PVPetrova V.G. Petrova V
Petrova V.G. Petrova V
VVVinogradova T.N. Vinogradova
Vinogradova T.N. Vinogradova
SASt. Petersburg St. Petersburg Charitable Foundation «Humanitarian Action»
St. Petersburg St. Petersburg Charitable Foundation «Humanitarian Action»